Advanced Medical Isotope Corporation (trading symbol QB:ADMD)
1021 N. Kellogg St. Kennewick, Washington 99336 US
T: 509.736.4000 F: 509.736.4007 E: info@isotopeworld.com

Tags

Latest News

Click here for more news and updates

Twitter • Industry News


Wed

27

Apr

2016

Dr. Albert S. DeNittis and Advance Medical Isoptope Founder CEO and Chairman, James C. Katzaroff, are Featured in a New Audio Interview at SmallCapVoice.com.

AUSTIN, Texas, April 27, 2016 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. (SCV) and Advanced Medical Isotope Corporation (or "AMI") (ADMD), (www.IsotopeWorld.com) a late stage development company engaged in the development of brachytherapy devices for therapeutic applications, announced today that a new audio interview with the Company is now available. The interview can be heard at http://smallcapvoice.com/blog/4-26-16-smallcapvoice-interview-with-advanced-medical-isotope-corporation-admd

 

AMI Founder, CEO and Chairman James C. Katzaroff and Dr. Albert S. DeNittis, Chief of Radiation Oncology at Lankenau Medical Center and Clinical Professor at Lankenau Institute for Medical Research who was recently appointed to AMI’s medical advisory board, both called in to SmallCapVoice.com, Inc. to discuss the applications, benefits and markets for the Y-90 RadioGel(TM) device. The Y-90 RadioGel(TM) device is one of several Y-90 brachytherapy products in development by AMI that may provide a safer, quicker and less expensive treatment to certain cancers including tumors deemed inoperable. Brachytherapy is the use of radiation to destroy cancerous tumors by placing a radiation source inside or next to the treatment area.

 

It was recently reported that by 2016 the U.S. brachytherapy market will reach $2 billion. Advanced Medical Isotope Corporation (ADMD) is a late stage radiation oncology focused medical device company engaged in the development of yttrium-90 based brachytherapy devices for the treatment of non resectable tumors. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area.

 

About SmallCapVoice.com

SmallCapVoice.com is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients' financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks they are interested in. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and their services, please visit http://www.smallcapvoice.com/services.html.

 

About Advanced Medical Isotope Corporation:

Advanced Medical Isotope Corporation (ADMD) is a late stage radiation oncology focused medical device company engaged in the development of yttrium-90 based brachytherapy devices for the treatment of non resectable tumors. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. The IsoPet Solutions division is focused on establishing the infrastructure necessary to provide product to veterinary clinics including regulatory clearances and compliance as well as providing product awareness and education to veterinary oncologists. The Company intends to outsource material aspects of manufacturing, distribution, sales and marketing for its products in the United States and to enter into licensing arrangements outside of the United States, though the Company will evaluate its alternatives before finalizing its plans. For more information, please visit our website, www.isotopeworld.com.

 

Safe Harbor Statement:

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.

Contact:

CONTACTS:

Advanced Medical Isotope Corporation
James C. Katzaroff, CEO
1021 N Kellogg
Kennewick WA 99336
509-736-4000

Investor Relations
Tyler M. Troup, B.Comm
Circadian Group IR, Managing Director
info@Circadian-Group.com
866-950-8300

For SmallCapVoice.com
Stuart T. Smith
512-267-2430
info@smallcapvoice.com

 

Write a comment

Comments: 0